In vitro efficacy of Colistin against multi-drug resistant Pseudomonas aeruginosa by minimum inhibitory concentration

Pakistan Journal of Pharmaceutical Sciences

Volumn 26, Issue 1, 2013, Pages 7-10

  Gill, Maria Mushtaq ^a   Rao, Javaid Usman ^a   Kaleem, Fatima ^a   Hassan, Afreenish ^a   Khalid, Ali ^a   Anjum, Rabia ^a  

^a ARMY MEDICAL COLLEGE   (Pakistan)

Author keywords

Anti biogram; Multi drug resistant Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; CEFOPERAZONE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULPERAZON; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISK DIFFUSION; IN VITRO STUDY; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PUS; RESPIRATORY TRACT INFECTION; URINE;

ANTI-BACTERIAL AGENTS; COLISTIN; DISK DIFFUSION ANTIMICROBIAL TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 84872198092     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ASM Submits Comments on "Multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria in healthcare settings. Expert proposal for a standardized international terminology." August 17, 2010. American Society for Microbiology © 2010.1752 N Street, N.W. Washington, D.C. 20036-2904 (202) 737-3600.
2. th ed. McGraw Hill Companies, p.188.
3. Cholley P, Gbaguidi-Haore H, Bertrand X, Thouverez M, Plésiat P, Hocquet D and Talon D (2010). Molecular epidemiology of multidrug-resistant Pseudomonas aeruginosa in a French university hospital. J Hosp Infect. 76(4): 316-9.
4. Clinical and Laboratory Standards Institute (CLSI)/NCCLS. Performance Standards for Antimicrobial susceptibility Testing; Twentieth Informational Supplement (M100-S20) (2010). Wayne, PA: CLSI/NCCLS. 25, pp. 62-63.
5. Customer Information Sheet Etest and Polymyxin B testing In the USA for investigational use only. Available online at http://www.abbiodisk.com/pdf/cis/ M0000536.pdf. [Accessed on 18 June 2011]
6. Etest Antimicrobial susceptibility testing for in vitro antibiotic diagnostic use. Available online at, http://www.abbiodisk.com/pdf/pi/75002206. pdf. [Accessed on 18 June 2011)
7. Falages ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P and Michalopoulos A (2005). Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis. 5: 24.
8. th Ed). INC. USA, p.135.
9. Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, Bodey GP and Raad II (2007). Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob. Agents Chemother., 51: 1905-1911.
10. Heijden IM, Levin AS, Pedri EHD, Fung L, Rossi F, Duboc G, Barone AA and Costa SF (2007). Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem resistant P. aeruginosa to polymyxins. Ann. Clin. Microbiol. Antimicrob., 6: 8.
11. th ed). Churchill Livingstone, pp. 435.
12. Lister PD, Wolter DJ and Hanson ND. (2009). Antibacterial resistant Pseudomonas aeruginosa : Clinical impact and Complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev., 22 (4): 582-680.
13. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falages ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Pateron DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. (2010). Multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-1 resistant (PDR) bacteria in healthcare settings. Expert proposal for a standardized international terminology. Available online at www.escmid.org/ESCD- Definitions-MDRXDRPDR-2010-pdf. [Accessed on 18 June 2011]
14. Nadeem SG, Qasmi SA, Afaque F, Saleem M and Hakim ST (2009). Comparison of the in vitro susceptibility of Clinical isolates of Pseudomonas aeruginosa in a local hospital setting in Karachi, Pakistan. BJMP, 2(4): 35-39.
15. Obritsch MD, Fish DN, MacLaren R and Jung R. (2005). Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa : Epidemiology and treatment options. Pharmacotherapy, 25: 1353-1364.
16. Rossolini GM and Mantengoli E (2005). Treatment and control of severe infections caused by multi-resistant Pseudomonas aeruginosa . Clin Microbiol Infect., 11 (4): 17-32.
17. Somily AM (2010). Comparison of Etest and disc diffusion methods for the in vitro evaluation of the antimicrobial activity of colistin in multi-drug resistant Gram-negative bacilli. Saudi Med. J. 31(5): 507-511.
18. Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro J and Garey KW (2010). Prevalence, mechanism and susceptibility of multidrug resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 54: 3717-3722.
19. Zia-Ul-Haq M, Ahmad M, Mehjabeen, Jehan N, Ahmad S, Qayum M and Marwat IK (2011). Antimicrobial screening of selected flora of Pakistan. Arch. Bio. Sci., 63: 691-695.